Abrdn Healthcare Investors (HQH)
$16.77
+0.21
(+1.27%)▲
Insights on Abrdn Healthcare Investors
Increasing Revenue
Revenue is up for the last 2 quarters, 2.33M → 75.23M (in $), with an average increase of 96.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 83.16M → -26.82M (in $), with an average decrease of 108.1% per quarter
Vs KKR
In the last 1 year, Kkr & Co. L.p. has given 92.4% return, outperforming this stock by 93.9%
Vs APO
In the last 3 years, Apollo Asset Management Inc has given 86.2% return, outperforming this stock by 117.3%
Performance
- $16.59$16.86$16.77
1.07%
Downside
Day's Volatility :1.59%
Upside
0.53%
- $13.11$17.08$16.77
21.82%
Downside
52 Weeks Volatility :23.24%
Upside
1.81%
Returns
| Period | Abrdn Healthcare Investors | Russel 2000 | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.53% | 0.0% | 0.0% |
6 Months | 9.82% | 0.0% | 0.0% |
1 Year | -1.93% | 0.0% | 0.0% |
3 Years | -31.13% | -22.6% | -22.6% |
Highlights
Market Capitalization | 838.3M |
Book Value | $18.84 |
Dividend Share | 1.61 |
Dividend Yield | 10.02% |
Earnings Per Share (EPS) | 1.09 |
PE Ratio | 15.19 |
PEG Ratio | 0.0 |
Profit Margin | 547.37% |
Operating Margin TTM | -21.92% |
Return On Assets TTM | -0.08% |
Return On Equity TTM | 6.1% |
Revenue TTM | 10.3M |
Revenue Per Share TTM | 0.21 |
Quarterly Revenue Growth YOY | 8.1% |
Gross Profit TTM | 8.3M |
Diluted Eps TTM | 1.09 |
Quarterly Earnings Growth YOY | -0.67 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Abrdn Healthcare Investors is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Abrdn Healthcare Investors | 0.48% | 9.82% | -1.93% | -31.13% | -12.61% |
 Blackstone Inc | -1.65% | 3.18% | 39.39% | 27.91% | 199.52% |
 Kkr & Co. L.p. | 5.01% | 37.16% | 90.88% | 86.23% | 337.72% |
 Blackrock, Inc. | 0.35% | 2.77% | 14.91% | -12.34% | 78.9% |
 Apollo Asset Management Inc | 4.55% | 29.7% | 65.32% | 103.01% | 277.43% |
 Brookfield Corp | 0.02% | 20.82% | 41.07% | -12.72% | 40.91% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Abrdn Healthcare Investors | 15.19 | 15.19 | 0.0 | 0.0 | 0.06 | 0.0 | 0.1 | 18.84 |
Blackstone Inc | 42.43 | 42.43 | 1.75 | 4.77 | 0.21 | 0.09 | 0.03 | 9.16 |
Kkr & Co. L.p. | 23.01 | 23.01 | 1.3 | 4.71 | 0.11 | 0.02 | 0.01 | 24.2 |
Blackrock, Inc. | 19.61 | 19.61 | 2.46 | 41.4 | 0.15 | 0.03 | 0.03 | 267.04 |
Apollo Asset Management Inc | 13.05 | 13.05 | 1.37 | 7.53 | 0.3 | 0.02 | 0.02 | 23.53 |
Brookfield Corp | 72.48 | 72.48 | NA | 4.55 | 0.03 | 0.02 | 0.01 | 26.75 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Abrdn Healthcare Investors | NA | $838.3M | -12.61% | 15.19 | 547.37% |
Blackstone Inc | Hold | $145.7B | 199.52% | 42.43 | 21.68% |
Kkr & Co. L.p. | Buy | $94.8B | 337.72% | 23.01 | 15.64% |
Blackrock, Inc. | Buy | $114.7B | 78.9% | 19.61 | 32.26% |
Apollo Asset Management Inc | Buy | $66.1B | 277.43% | 13.05 | 16.23% |
Brookfield Corp | Buy | $67.4B | 40.91% | 72.48 | 1.14% |
Company Information
tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
Organization | Abrdn Healthcare Investors |
Employees | 0 |
CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$16.77
+1.27%
Keyarch Acquisition Corp
$16.77
+1.27%
Connexa Sports Technologies Inc
$16.77
+1.27%
Us Value Etf
$16.77
+1.27%
First Wave Biopharma Inc
$16.77
+1.27%
Global X Msci Next Emerging
$16.77
+1.27%
Fat Projects Acquisition Corp
$16.77
+1.27%
Capital Link Global Fintech
$16.77
+1.27%
Applied Uv Inc
$16.77
+1.27%